SCHEMBL9890671

SCHEMBL9890671

O=C(O)Cc1cc(F)ccc1-c1cccc(F)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 5/20 0.50
KDM4E B2RXH2 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
TBXA2R P21731 1/20 0.50
PTGDR Q13258 1/20 0.50
PTGER1 P34995 2/20 0.47
PTGER4 P35408 2/20 0.47
PTGER3 P43115 2/20 0.47
PTGER2 P43116 2/20 0.47
FFAR1 O14842 2/20 0.46
FFAR4 Q5NUL3 2/20 0.46
DCLRE1B Q9H816 1/20 0.46
PPARG P37231 2/20 0.45
TSHR P16473 1/20 0.44
PTGS1 P23219 2/20 0.44
AKR1A1 P14550 1/20 0.42
AKR1B1 P15121 1/20 0.42
NR4A1 P22736 1/20 0.42
NR4A2 P43354 1/20 0.42
NR4A3 Q92570 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3731501 0.90 FFAR1 (0.54) PTGDR2TBXA2RPTGDRPTGER1PTGER4
SCHEMBL9890677 0.88 PTGS2 (0.47) PTGDR2KDM4ESMN1; SMN2TBXA2RPTGDR
SCHEMBL9890655 0.88 PPARG (0.49) PTGDR2TBXA2RPTGDRPTGER1PTGER4
SCHEMBL9890674 0.88 SUCNR1 (0.46) PTGDR2KDM4ESMN1; SMN2TBXA2RPTGDR
SCHEMBL9890666 0.87 PTGDR2 (0.50) PTGDR2KDM4ESMN1; SMN2TBXA2RPTGDR
SCHEMBL9105295 0.87 PTGER1 (0.57) PTGDR2KDM4ESMN1; SMN2TBXA2RPTGDR
SCHEMBL9890679 0.86 KDM4E (0.49) PTGDR2KDM4ESMN1; SMN2TBXA2RPTGDR
SCHEMBL9890774 0.86 ICMT (0.54) FFAR1FFAR4DCLRE1B
SCHEMBL9892655 0.86 PTGDR2 (0.47) PTGDR2KDM4ESMN1; SMN2TBXA2RPTGDR
SCHEMBL3749563 0.85 TSHR (0.47) PTGDR2FFAR1FFAR4PPARGTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 PTGDR2 1062/4885KDM4E 829/4885SMN1; SMN2 2980/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 PTGDR2 1062/4885KDM4E 829/4885SMN1; SMN2 2980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.